Domů › Srdeční selhání › Missouri › Kansas City
Klinické studie Srdeční selhání v Kansas City, MO
25 studií pro Srdeční selhání hledá účastníky v lokalitách v Kansas City a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
ELEVATE-HFpEF Clinical Study
Probíhá nábor
- Saint Lukes Mid America Heart Institute, Kansas City
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Probíhá náborFáze 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Probíhá náborFáze 3
- Kansas City VA Medical Center, Kansas City
- North Kansas City Hospital, North Kansas City · Vzdálenost 2 mi
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Probíhá náborFáze 3
- Kansas City VA Medical Center, Kansas City
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Probíhá náborFáze 3
- Research Site, Kansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Probíhá náborFáze 3
- Saint Luke's Hospital of Kansas City, Kansas City
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Probíhá nábor
- Saint Luke's Hospital of Kansas City, Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Probíhá náborFáze 3
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Probíhá náborFáze 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Probíhá náborFáze 3
- Kansas City, MO Investigative Site 10002, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Probíhá náborFáze 3
- CON-10002 Kansas City, MO Investigative Site, Kansas City
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
Probíhá náborObservační studie
- St. Luke's Hospital of Kansas City, Kansas City
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Probíhá náborFáze 2
- Local Institution - 145, Kansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Probíhá náborObservační studie
- Kansas City, Kansas City
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Probíhá náborObservační studie
- St. Luke's Mid-America Heart Institute, Kansas City
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Probíhá náborFáze 3
- Tenax Investigational Site, Kansas City
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Probíhá náborFáze 3
- Clinical Research Consultants, JCCT Co, Kansas City
Assessment of CCM in HF With Higher Ejection Fraction
Probíhá nábor
- St. Lukes Hospital Kansas City (Mid America Heart Institute), Kansas City
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Probíhá náborFáze 3
- FIN-10002 Kansas City, MO Investigational Site, Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Probíhá nábor
- St. Lukes/ Mid-American Heart Institute, Kansas City
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Probíhá náborFáze 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Probíhá náborFáze 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Probíhá nábor
- St. Luke's Hospital, Kansas City
CCM OPEN HF Registry
Probíhá náborObservační studie
- Saint Luke's Hospital Mid America Heart Institute, Kansas City
- Saint Luke's Hospital of Kansas City, Kansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
Probíhá náborObservační studie
- Saint Luke's Health System, Kansas City
Studie Srdeční selhání v jiných městech
- New York City, NY51 studií
- Boston, MA44 studií
- Dallas, TX42 studií
- Houston, TX36 studií
- Cleveland, OH33 studií
- Chicago, IL31 studií
- Philadelphia, PA31 studií
- San Francisco, CA29 studií
- Durham, NC26 studií
- St. Louis, MO26 studií
- Atlanta, GA25 studií
- Cincinnati, OH24 studií
Další studie v Kansas City
- Rakovina prsu34 studií
- Nemalobuněčný plicní karcinom31 studií
- Rakovina (všechny typy)21 studií
- Rakovina plic19 studií
- Kolorektální karcinom16 studií
- Metastatický karcinom15 studií
- Akutní myeloidní leukemie15 studií
- Rakovina prostaty14 studií
- Rakovina vaječníků11 studií
- Obesity11 studií
- Diabetes mellitus 2. typu11 studií
- Kardiovaskulární onemocnění11 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.